Vivani Medical Inc. (VANI)

In November 2025, Vivani Medical provided a business update and reported its Third Quarter 2025 Financial Results, highlighting strategic advancements including the successful completion of the LIBERATE-1 clinical trial and announcing plans to initiate a Phase 1 clinical study for the NPM-139 semaglutide implant in the first half of 2026. In October 2025, the company announced the pricing and closing of a common stock offering, which, along with a private placement, generated approximately $25.7 million in cash and commitments to support the accelerated development of NPM-139 and secure its financial position into 2027. In September 2025, Vivani Medical provided an update on clinical development plans for its NPM-139 Semaglutide Implant, and the CEO presented at the Emerging Growth Conference and discussed the company's implantable drug delivery technology on The Bio Report podcast. In August 2025, Vivani Medical provided a business update, including a $10M equity financing, and reported Second Quarter 2025 financial results. In July 2025, the company's stock price increased by 9.92% over the last 12 months, with an 8.13% year-to-date return as of early January 2026, but decreased by 4.32% in the month leading up to January 2026.

The provided search results do not contain explicit information about demand seasonality for Vivani Medical, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by the prevalence of chronic diseases and the efficacy and convenience of its treatment solutions, rather than traditional seasonal fluctuations. Factors such as new clinical data releases, regulatory approvals, and competitive landscape changes could influence market interest and adoption more significantly than seasonality.

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative solutions for chronic diseases through miniaturized, ultra-long-acting subdermal drug implants, leveraging its proprietary NanoPortal™ technology to ensure precise and sustained medication delivery. The company operates within the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals industries, with a sub-industry classification of Medical Devices & Instruments. The company's major products and pipeline candidates, all utilizing the NanoPortal™ platform, include NPM-115 (Exenatide Implant), NPM-139 (Semaglutide Implant), NPM-133 (Semaglutide Implant), and OKV-119 (Exenatide Implant). Vivani Medical also has a Neuromodulation Division, which includes activities from Cortigent and its subsidiary in Switzerland, with plans to spin it off as an independent publicly traded company.

Vivani Medical, Inc. is headquartered in Alameda, California, United States, with operations extending to Australia, where its first-in-human Phase 1 trial (LIBERATE-1) for the exenatide implant began, and Switzerland, through its Cortigent subsidiary. Revenue breakdown indicates sales in the United States, Italy, and China.

Vivani Medical's brand reputation in the past year is centered around its innovative NanoPortal™ technology and its potential to address critical healthcare challenges. The successful completion of the LIBERATE-1 first-in-human study and positive preclinical data for their semaglutide implant (NPM-139) have contributed positively to their reputation. The company's participation in various investor and scientific conferences indicates active engagement with the investment and scientific communities. The company's status as a clinical-stage biopharmaceutical company means its reputation is closely tied to the success of its clinical trials and regulatory approvals, and ongoing investor concerns about market positioning and lack of positive catalysts could subtly influence brand perception among investors.

Vivani Medical, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. As of late 2025, Vivani Medical, Inc. has 38 institutional owners holding a total of 3,987,968 shares, representing approximately 5.37% to 6.78% of the company's stock. Insiders hold a significant portion of the company's stock, approximately 43.80% to 45.2%, with Gregg Williams being the largest individual shareholder. Retail investors hold approximately 50.63% of the stock.